Published in Mult Scler on August 01, 2000
Treatment of acute relapses in multiple sclerosis. Neurotherapeutics (2013) 1.05
Role of toll-like receptors in multiple sclerosis. Am J Clin Exp Immunol (2013) 0.94
Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry (2006) 0.92
Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance. Eur J Clin Pharmacol (2014) 0.90
Pediatric multiple sclerosis. NeuroRx (2006) 0.84
Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review. Mult Scler Int (2011) 0.82
Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trial. Arch Med Sci (2015) 0.78
Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? Int J Mol Sci (2012) 0.78
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurol Sci (2012) 0.78
Astragalosides from Radix Astragali benefits experimental autoimmune encephalomyelitis in C57BL /6 mice at multiple levels. BMC Complement Altern Med (2014) 0.77
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses. BMC Neurol (2015) 0.77
A predictive model for corticosteroid response in individual patients with MS relapses. PLoS One (2015) 0.76
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics (2016) 0.75
Persistent activation of microglia and NADPH drive hippocampal dysfunction in experimental multiple sclerosis. Sci Rep (2016) 0.75
Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int (2016) 0.75
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. Mult Scler (2013) 5.40
Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology (2011) 5.16
A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med (2001) 4.87
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet (2000) 4.81
Polymersomes: tough vesicles made from diblock copolymers. Science (1999) 4.76
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA (2001) 4.75
Venous angioplasty in patients with multiple sclerosis: results of a pilot study. Eur J Vasc Endovasc Surg (2011) 4.68
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia (2012) 4.44
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med (2001) 4.19
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
A transformation of self-discrimination response functions in accordance with the arbitrarily applicable relations of sameness, more than, and less than. J Exp Anal Behav (1995) 3.70
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology (2011) 3.62
Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med (1998) 3.62
Serum-free cell culture: a unifying approach. Cell (1980) 3.41
Preparation of tubulin from brain. Methods Enzymol (1982) 3.39
The stabilization of proteins by sucrose. J Biol Chem (1981) 3.34
Methods for growth of cultured cells in serum-free medium. Anal Biochem (1980) 3.27
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest (1999) 3.21
Race/ethnic differences in AD survival in US Alzheimer's Disease Centers. Neurology (2007) 3.18
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol (1995) 3.06
Rapid penicillinase paper strip test for detection of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae. Antimicrob Agents Chemother (1977) 3.02
Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer (1999) 2.95
Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun (1980) 2.91
A transfer of functions through derived arbitrary and nonarbitrary stimulus relations. J Exp Anal Behav (1993) 2.89
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
The association of cancer and the nephrotic syndrome. Ann Intern Med (1966) 2.88
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Identification of the gene that, when mutated, causes the human obesity syndrome BBS4. Nat Genet (2001) 2.77
Comparison of CT scan muscle measurements and isokinetic trunk strength in postoperative patients. Spine (Phila Pa 1976) (1989) 2.70
Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet (1997) 2.69
The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J (1996) 2.64
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther (1996) 2.63
The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology (1997) 2.61
Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell (1994) 2.60
A transformation of respondently conditioned stimulus function in accordance with arbitrarily applicable relations. J Exp Anal Behav (1997) 2.56
Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem (1996) 2.55
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology (2004) 2.50
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2000) 2.48
Binding sites in Escherichia coli dihydrofolate reductase communicate by modulating the conformational ensemble. Proc Natl Acad Sci U S A (2000) 2.47
The role of liver biopsy in chronic hepatitis C. Hepatology (2001) 2.47
Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet (1999) 2.42
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology (1999) 2.40
Use of alternative techniques of hysterectomy in Ohio, 1988-1994. N Engl J Med (1996) 2.40
Imaging protein kinase Calpha activation in cells. Science (1999) 2.37
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Infect Immun (1991) 2.29
Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun (1998) 2.29
Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem (1997) 2.28
A transfer of self-discrimination response functions through equivalence relations. J Exp Anal Behav (1994) 2.24
Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line. J Immunol (1982) 2.22
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16
Cytolysis induced by human lymphotoxin. Am J Pathol (1972) 2.14
Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem (1998) 2.12
Cyclin D1 and prognosis in human breast cancer. Int J Cancer (1996) 2.11
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol (2000) 2.11
Characterization of Candida albicans adherence to human vaginal epithelial cells in vitro. Infect Immun (1983) 2.07
Analyzing derived stimulus relations requires more than the concept of stimulus class. J Exp Anal Behav (1997) 2.06
Application of fluorescence energy transfer and polarization to monitor Escherichia coli cAMP receptor protein and lac promoter interaction. Proc Natl Acad Sci U S A (1990) 2.05
Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol (2006) 2.04
Partial specific volumes and interactions with solvent components of proteins in guanidine hydrochloride. Biochemistry (1974) 2.03
The reconstitution of microtubules from purified calf brain tubulin. Biochemistry (1975) 2.02
Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res (1999) 2.02
Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler (2007) 1.99
In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry (1977) 1.99
Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun (1997) 1.99
A new nomenclature for the cytoplasmic ribosomal proteins of Saccharomyces cerevisiae. Nucleic Acids Res (1997) 1.99
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol (1998) 1.97
The kinetics of interleukin 1 secretion from activated monocytes. Differences between interleukin 1 alpha and interleukin 1 beta. J Biol Chem (1988) 1.95
Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation (1999) 1.93
An analysis of allelic variation in the ABCA4 gene. Invest Ophthalmol Vis Sci (2001) 1.90
Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology (2011) 1.89
Thalamic atrophy and cognition in multiple sclerosis. Neurology (2007) 1.87
Integration of synthetic globin genes into an E. coli plasmid. Nucleic Acids Res (1976) 1.85
Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis (1993) 1.84
Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis (1986) 1.83
Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res (1999) 1.82
Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol (2000) 1.81
Establishment of continuous cultures of thy1.2+, Lyt1+, 2-T cells with purified interleukin 3. Cell (1981) 1.80
The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun (1997) 1.80
Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun (1999) 1.80